

## Spondyloarthritis Committee meeting

**Date:** 15<sup>th</sup> and 16<sup>th</sup> June 2015

**Location:** Derwent, NICE Office, London

**Minutes:** Draft

<b>Committee members present:</b>		
	<b>Day 1</b>	<b>Day 2</b>
Gary McVeigh (Chair) (GM)	Present for all items	Present for all items
Amanda Isdale (AI)	Present for all items	Present for all items
Nicky Goodson (NG)	Present for all items	Present for all items
Louise Warburton (LW)	Present for all items	Present for all items
Tina Hawkins (TH)	Present for all items	Present for all items
Carol McCrum (CM)	Present for all items	Present for all items
Charlotte Davis (CD)	Present for all items	Present for all items
David Chandler (DC)	Present for all items	Present for all items
Debbie Cook (DCo)	Present for all items	Present for all items

<b>Co-opted experts present:</b>		
	<b>Day 1</b>	<b>Day 2</b>
Alastair Denniston <i>Ophthalmologist</i>	N/A	Present for all items
Tim Orchard <i>Gastroenterologist</i>	N/A	Present for the morning
Philip O'Connor <i>Radiologist</i>	N/A	On teleconference for the morning

<b>In attendance:</b>		
	<b>Day 1</b>	<b>Day 2</b>
Sofia Dias (SD) <i>Technical Support Unit</i>	Present for the morning	N/A
Edna Keeney	Present for the morning	N/A

**SA GDG 6 minutes**

<i>Technical Support Unit</i>		
Louise Shires <i>Guideline Commissioning Manager</i>	Present for all	N/A
Sue Spiers <i>Associate Director</i>	Present for the morning	Present for the morning
Hugh McGuire (HM) <i>Technical Adviser</i>	Present for the morning	Present for the morning
Steven Ward (SW) <i>Health Economist</i>	Present for all	Present for all
Margaret Derry <i>Project Manager</i>	Present for all	Present for all
Jemma Deane <i>Information Specialist</i>	Present for all	Present for all
Lucy Hoppe (LH) <i>Technical Analyst</i>	N/A	Present for the afternoon
Shelly Patel <i>Medicines Advice Senior Adviser</i>	Present for the morning	N/A
<b>Observing:</b>		
Rosa Domingues <i>NICE work placement</i>	Present for all	Present for all

<b>Apologies:</b>	
Jon Packham	Committee member
Issak Bhojani	Committee member
Katherine McAllister	Technical Analyst

Notes

Day 1

**1. Welcome, minutes of the last meeting, declarations of interest and objectives for the meeting**

The Chair welcomed the Committee members and attendees to the sixth guideline committee meeting.

Apologies were noted, as recorded above and minutes of the last meeting were agreed as an accurate record with one minor correction. The Chair provided a brief overview and objectives of the day highlighting the information that would be discussed.

All GDG members were asked to share any new conflicts of interest which have not previously been declared. No new interests were declared.

**2. Review question 20 – comparative effectiveness of non-steroidal anti-inflammatory drugs for managing axial spondyloarthritis**

SD gave the committee a brief introduction to network meta-analysis (NMA), before talking through the NMA results for non-steroidal anti-inflammatory drugs (NSAID's). Outcomes reported included pain, withdrawals due to adverse events and withdrawals due to lack of efficacy.

SD highlighted that the NMA only looked across NSAID's and did not look at, say, paracetamol. In addition, there were not many recent studies available.

The group discussed the findings, noting that a comparison against naproxen would be valuable. They agreed that of the three prioritised outcomes, pain was the highest priority and that for the majority of NSAID's reduction of pain outweighed the risk of adverse events.

The group considered and drafted recommendations.

**3. Health economics update**

SW gave an update on health economics, including a brief recap of how health economics is carried out at NICE. He gave a review of the economic literature considered for review question 20, noting the 2 papers which had been identified and suggesting considerations for the GDG.

**4. Agreeing review protocols**

SW and LH talked the group through protocols for all but one of the remaining review questions, finalising study design, population, outcomes, inclusion and exclusion

## SA GDG 6 minutes

criteria.

It was highlighted that review question 13 may be covered by the NICE transition guideline currently under development. It was agreed to investigate this further.

### **5. Summary of day**

There were no additional matters arising. The Chair summarised the discussions from the day, thanked the group for their work and closed day 1 of the meeting.

## SA GDG 6 minutes

### Day 2

#### 1. Recap of day 1 and objectives for day 2

The Chair recapped the discussions from day 1 and summarised the objectives for day 2. He welcomed the co-opted experts to the meeting and asked them to briefly introduce themselves to the committee.

#### 2. Review question 32 – long term complications associated with spondyloarthritis

HM noted that there is a large degree of overlap between these two questions and explained that both questions would need revisiting.

The group reviewed the protocol and noted that it would be helpful to also include retrospective studies, but with a particular focus on primary care. A clinical pathway for general practice would be especially valuable.

#### 3. RQ 12 – Indications for referral for specialist advice at initial diagnosis

HM presented the clinical reviews for review question 12: *‘What are the indications (signs, risk factors, test or scan findings) for referral for specialist advice at initial diagnosis?’*

HM went through the review protocol, search strategies and included evidence used to inform these questions. The GDG discussed the evidence available, and discussed whether NSAID responsiveness would be better included as part of review questions 1 and 2. This would be a better fit. All agreed that education about what inflammatory back pain is would be valuable in primary care.

Following discussion the GDG went on to consider and draft recommendations.

The committee were asked to look at the linking evidence to recommendations table which would underpin the review for question 12. The group went through this carefully, making amendments and coming to a final consensus about their interpretation of the evidence review which was conducted.

#### 4. Any other business

There were no additional matters arising. The Chair summarised the discussions from the day, thanked the group for their work and closed the meeting.

**Date of next meeting:** 29<sup>th</sup> July 2015

**Location of next meeting:** NICE offices, London